SBRT 2016

Retrospective cohorts

Author/year

# pts. LNmet/t otal

Primary

Fract x dose

Local control 2-years

Survival 2-years

Severe morbidity

Kang 2010

26/59

CRC

3 x 12-17Gy

66%

66%

Grade 4 (n=2)

Bignardi 2011

19

Mixed

6 x 7.5Gy

78

NA

Grade 3 (n=1)

Prostate cancer

3 x 9-10Gy; 5 x 7Gy

Petrongari 2011

12/12

3/12

NA

No

64% (3-years)

60% (3-years)

Grade>3 (n=3)

Bae 2012

18/41

CRC

3 x 15-17Gy

Jereczek-Fossa 2012

Prostate cancer Prostate cancer

14/14

3 x 10Gy

14/14

65%

No

Bercovic 2013

11/24

10 x 5Gy

11/11

NA

No

10 x 4-5Gy; 3 x 12Gy; 5 x 8.5Gy 3 x 15Gy (isocenter)

32% (3-years)

De Vin 2014

88/309

Mixed

33%

NR

Fode 2015

6/201

Mixed (CRC)

6/6

58%*

No

Ost 2016

77/119

Prostate

Varying

93%

48%*

No